Whalesbook
So, bhaiyo aur behno, India ke pharma market mein ekdum se andaaz mein badlav aa gaya hai, khaas kar GLP-1 drugs ke liye. Pata hai kyun? Kyunki Novo Nordisk ki blockbuster drug, semaglutide, jo diabetes aur weight loss mein kaam aati hai, uska patent March 20 ko India mein expiry ho gaya. Aur jaise hi patent gaya, wahan 13 companies ne 26 alag-alag generic brands launch kar diye! Market mein bhari competition aa gaya hai.
Abhi interesting baat ye hai ki Novo Nordisk ke apne brands—jaise Rybelsus, Wegovy, aur Ozempic—ne revenue mein bas thoda hi dip dekha hai. February mein jo ₹47 crore ka revenue tha, woh March mein gir ke bas ₹45 crore ho gaya. Matlab, unka hold abhi bhi kaafi strong hai.
Lekin doosri taraf, Eli Lilly ki tirzepatide, jo abhi bhi patented hai, uske sales mein achha khasa 21% ka dip aaya hai. March mein revenue ₹114 crore ho gaya, jo ki uske launch hone ke baad pehla monthly sales decline hai. Lagta hai generics ka pressure abhi se dikh raha hai.
Is patent expiry ka sabse bada fayda hua hai Torrent Pharmaceuticals jaise Indian companies ko. Torrent ne ₹4.7 crore ki sales ki, Dr. Reddy's Laboratories ne ₹1.9 crore, aur Zydus Healthcare aur Lupin ne bhi ₹1.4 crore ki sales ki. Yeh figures batate hain ki GLP-1 market ab bara ho raha hai, kyuki drugs ab zyada affordable aur accessible ho gaye hain.
Abhi valuations ki baat karein toh, bada player Eli Lilly ka market cap lagbhag $871.60 billion aur Novo Nordisk ka $176.49 billion hai. Wahi, Indian players jaise Torrent Pharma ka $15.20 billion market cap hai, lekin unka P/E ratio 64.32x hai. Yeh 64.32x ka P/E ratio dikhata hai ki investors ko Torrent se future mein bahut zyada growth ki umeed hai, shayad thodi zyada bhi!
Novo Nordisk ki strategy change ho rahi hai. Woh Emcure aur Abbott jaise companies ke saath tie-up kar rahe hain aur prices bhi adjust kar rahe hain. Yeh sab isliye kar rahe hain taaki generics ke saamne apni market share bana rahein aur accessibility ko badhaayein.
Lekin asli challenge abhi shuru hua hai. Itne saare generics ke aane se profit margins par pressure aayega. Agar Novo Nordisk ko prices kam karne pade, toh unke blockbuster drug ki profitability kam ho sakti hai. Aur Torrent Pharma jaise companies jinka valuation high hai, unko apna growth maintain karna mushkil ho sakta hai agar price wars shuru ho gayi.
Analysts keh rahe hain ki aane wale hafton mein aur bhi aggressive product launches hongi. Is GLP-1 segment mein growth kaafi tez rehne wali hai. Ab dekhna yeh hai ki Novo Nordisk kaise is badhti hui competition ko manage karta hai aur apni market position maintain kar paata hai ya nahi. Poora market ab aur bhi interesting hone wala hai!